Aura Biosciences, Inc. — Form 8-K
Filed July 8, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Aura Biosciences appointed Jeremy Bender, Ph.D., M.B.A., to its Board of Directors on July 8, 2026. Bender most recently served as CEO of Day One Biopharmaceuticals, which was acquired by Servier for approximately $2.5 billion in 2026. The filing also updates the Non-Employee Director Compensation Policy (effective June 11, 2026), specifying cash retainers ($40,000 base annual board member retainer plus committee fees), initial equity grants (60,000 stock options and 30,000 RSUs capped at $800,000 value), and annual equity awards (30,000 options and 15,000 RSUs capped at $400,000 value), with a maximum annual compensation cap of $750,000 per director ($1,000,000 in first year).
Why this rating
Board appointment is routine corporate governance. Bender's M&A experience may aid Aura's strategy, but compensation policy is standard practice. No material financial impact relative to $321M market cap.
See more from July 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.